Subcutaneous regular insulin was used in all participants with DM1 during the OGTT, this likely led to the lower insulin levels and more pronounced hyperglycemia following OGTT in the DM1 group, which could impact vascular responses. The gene discussed is INS; the disease is Hyperglycemia.